Insulin Aspart vs. Insulin Lispro vs. Regular Insulin in Paediatric Population
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1
- Registration Number
- NCT00071448
- Lead Sponsor
- Novo Nordisk A/S
- Brief Summary
This trial is conducted in the United States of America (USA). The aim of this trial is to to determine whether insulin aspart can be used effectively and safely in paediatric patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 378
Inclusion Criteria
- Pediatric patients with Type 1 diabetes for at least one year
- HbA1c less than 12%
- Willing to administer at least 3 injections per day
- Willing to perform self monitored blood glucose (SMBG) at least 4 times per day, includes subject and/or parent/guardian, as necessary
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method HbA1c (glycosylated haemoglobin A1c)
- Secondary Outcome Measures
Name Time Method FPG (fasting plasma glucose)
Trial Locations
- Locations (1)
Novo Nordisk Investigational Site
🇺🇸Madison, Wisconsin, United States
Novo Nordisk Investigational Site🇺🇸Madison, Wisconsin, United States